Canada is the first G7 country to approve generic semaglutide. What Health Canada approved in 2026, why the patent lapsed, pricing and availability — and how prescription generics differ from research-grade semaglutide.
In 2026, Canada became the first G7 country to approve a generic version of semaglutide — the compound behind Ozempic and Wegovy. It is a notable regulatory milestone that has driven a wave of search interest. Here is a factual summary of what happened, with sources, plus an important clarification about what it does and does not mean for research-grade semaglutide. This is informational reporting on public regulatory news, not medical or legal advice.
Generic entry became possible because Novo Nordisk's key Canadian patent protection for semaglutide lapsed, and the compound's data-exclusivity period in Canada expired in early 2026. Multiple outlets reported that Novo Nordisk allowed the relevant Canadian patent to lapse — a maintenance fee was not paid — and characterised it as a deliberate strategic decision rather than an oversight. Crucially, Canada's protection ran out years earlier than in the United States, where semaglutide patent coverage extends into the early 2030s (drug discovery trends, legal.io).
Generic semaglutide reached Canadian pharmacy shelves in May 2026, sold at major chains and telehealth platforms. Reporting put the generic (diabetes) at roughly one-third of the brand price — on the order of about $78 versus about $240 for a four-week supply at wholesale (The Globe and Mail).
One important nuance: a Health Canada authorization confirms the generic is pharmaceutically equivalent, but it does not automatically make it interchangeable at the pharmacy counter. Interchangeability is decided province by province, so automatic substitution and generic-only reimbursement roll out on different timelines across the country.
As of mid-2026, several additional generic semaglutide submissions remained under Health Canada review, with decisions expected over the following months. The generic market is expected to keep broadening.
This is the part that matters for anyone researching semaglutide as a compound. The products above are prescription pharmaceuticals: they hold Health Canada Notices of Compliance and Drug Identification Numbers (DINs), meet bioequivalence and quality standards, and are dispensed by pharmacies to patients.
Research-grade semaglutide — the kind sold by research-chemical and peptide suppliers — is a different regulatory category entirely. It is not a Health Canada-approved drug, has no DIN, is not evaluated or approved for human use, and is supplied strictly for laboratory research use only. The 2026 generic approvals do not change any of that: research-grade material is not a generic Ozempic, not a substitute for a prescription medicine, and not for human consumption. For what research-grade semaglutide is — and isn't — see the semaglutide research hub.
Is generic semaglutide available in Canada? Yes. Health Canada approved the first generic semaglutide (a generic of Ozempic) in April 2026, followed by further approvals, making Canada the first G7 country to do so. These are prescription products dispensed by pharmacies.
Why did generic semaglutide arrive in Canada before the US? Semaglutide's patent and data-exclusivity protection in Canada expired years earlier than in the US, where protection extends into the early 2030s. Reporting indicates Novo Nordisk allowed the key Canadian patent to lapse.
Is generic semaglutide cheaper than Ozempic? Reporting put the generic at roughly one-third of the brand price for the diabetes product. Actual out-of-pocket cost depends on province, pharmacy, insurance, and province-by-province interchangeability decisions.
Is research-grade semaglutide the same as the approved generic? No. Approved generics are prescription pharmaceuticals with Health Canada DINs, dispensed by pharmacies. Research-grade semaglutide is not a Health Canada-approved drug, has no DIN, and is supplied for laboratory research use only — not for human use.